Note: Ingredients listed on restricted chemical lists
EC/CAS
9004-65-3
Name of the chemical
methylhydroxypropylcellulose
Concentration
N/A
EC/CAS
200-559-2/63-42-3
Name of the chemical
Lactose C12H22O11
Concentration
N/A
EC/CAS
232-674-9/9004-34-6
Name of the chemical
cellulose
Concentration
N/A
EC/CAS
500-038-2/25322-68-3
Name of the chemical
polyethyleneglycol
Concentration
N/A
EC/CAS
232-679-6/9005-25-8
Name of the chemical
Starch
Concentration
N/A
EC/CAS
200-338-0/57-55-6
Name of the chemical
1,2-propanediol
Concentration
N/A
EC/CAS
238-877-9/14807-96-6
Name of the chemical
Talc
Concentration
N/A
EC/CAS
247-368-0/25956-17-6
Name of the chemical
Disodium 6-hydroxy-5-[(2-methoxy-4-sulphonato-m-tolyl)azo]naphthalene-2-sulphonate (17); (CI 16035)
Concentration
N/A
EC/CAS
240-589-3/9003-39-8
Name of the chemical
polyvinylpyrrolidone
Concentration
16251-28-
EC/CAS
500-019-9/9005-65-6
Name of the chemical
polyethyleneglycol sorbitan monooleate
Concentration
N/A
EC/CAS
13463-67-7
Name of the chemical
Reaction mass of titanium dioxide and silver chloride
Concentration
236-675-
EC/CAS
200-413-8
Name of the chemical
Methotrexate (INN)
Concentration
N/A
EC/CAS
209-150-3
Name of the chemical
Aluminium, zinc, magnesium and calcium stearates
Concentration
N/A
General Information
Revision date
2013-03-06
Product name
Methotrexate Tablets Trexall (methotrexate tablets, USP)
Chemical name
For Active Ingredient
1.2.1 Relevant identified uses
Pharmaceutical for Human Use
Manufacturer Name
TEVA
Emergency telephone
1-800/424-9300, 01-703-527-3887
Icons in SDS
Company Information
company name
TEVA
e-mail address of the competent person responsible for the Safety Data Sheet
TevaSDSRequest@tevapharm.com
Section 2
SECTION 2: Hazards identification
Product definition
This product consists of oval, odorless tablets that are yellow (2.5 mg), green (5 mg), blue (7.5 mg), pink (10 mg) or purple (15 mg). Health Hazards In the workplace, exposure via inhalation and skin contact may cause irritation. Eye contact can cause mechanical irritation. In therapeutic use, the most common adverse effects of oral dosage have been nausea and vomiting, gastrointestinal bleeding. More serious hematological and digestive system effects have been reported. May cause harm to the fetus and have adverse effects on fertility for both genders. Serious allergic reactions have occurred when administered for therapeutic use. These effects may be possible as a result of workplace exposure. Refer to Section 11 (Toxicological Information) for additional information on adverse effects. Flammability Hazards: This product requires substantial pre-heating before ignition occurs. When involved in a fire, this product may decompose and produce irritating vapors and toxic compounds (including carbon, magnesium, silicon, sodium and nitrogen oxides). Reactivity Hazards: This product is not reactive.
Environmental hazards
Negligible. Emergency Recommendations Emergency responders must wear personal protective equipment suitable for the situation to which they are responding.